Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
Status: | Completed |
---|---|
Conditions: | Neurology, Women's Studies |
Therapuetic Areas: | Neurology, Reproductive |
Healthy: | No |
Age Range: | Any |
Updated: | 3/24/2019 |
Start Date: | February 1993 |
End Date: | February 1997 |
Randomized Clinical Trial of Antenatal Phenobarbital in the Prevention of Neonatal Intracranial Hemorrhage
This large randomized trial tested whether phenobarbital given to a pregnant woman about to
deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to
32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were
randomized to phenobarbital or usual care. They were treated until they deliver or the fetus
reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos
corrected age for neurodevelopmental outcome.
deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to
32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were
randomized to phenobarbital or usual care. They were treated until they deliver or the fetus
reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos
corrected age for neurodevelopmental outcome.
The administration of phenobarbital to pregnant women before delivery has been thought to
decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this
potential neuroprotective therapy further, we determined the effect of antenatal
administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and
early death. Women who were 24 to 33 weeks pregnant and who were expected to deliver their
infants within 24 hours were randomly assigned to receive either intravenous phenobarbital
(10 mg/kg body weight) or placebo, followed by maintenance doses until delivery or 34 wks
gestation. Infants less than 34 wks at birth underwent serial cranial ultrasonography to
detect the presence of intracranial hemorrhage. The sample size of 1038 pregnancies was based
on an intracranial hemorrhage rate of 20 percent in the placebo and less than 12 percent in
the phenobarbital group; 90 percent power; a 5 percent two-tailed type 1 error; and an 8
percent noncompliance rate. The twin with the highest grade of intracranial hemorrhage was
included.
Degree of maternal sedation was evaluated after administration of study drug. Neonatal
ultrasound exams were performed at 3-5 days, 10-14 days, and 38-42 wks postmenstrual age;
neonatal medications were recorded during the first week of life; treatments, and outcomes
were recorded through death, discharge, or 120 days, whichever occurred first.
Neurodevelopmental outcome was evaluated at 18-22 months corrected age by certified examiners
masked to treatment status.
decrease the frequency of intracranial hemorrhage in preterm infants. To evaluate this
potential neuroprotective therapy further, we determined the effect of antenatal
administration of phenobarbital on the frequency of neonatal intracranial hemorrhage and
early death. Women who were 24 to 33 weeks pregnant and who were expected to deliver their
infants within 24 hours were randomly assigned to receive either intravenous phenobarbital
(10 mg/kg body weight) or placebo, followed by maintenance doses until delivery or 34 wks
gestation. Infants less than 34 wks at birth underwent serial cranial ultrasonography to
detect the presence of intracranial hemorrhage. The sample size of 1038 pregnancies was based
on an intracranial hemorrhage rate of 20 percent in the placebo and less than 12 percent in
the phenobarbital group; 90 percent power; a 5 percent two-tailed type 1 error; and an 8
percent noncompliance rate. The twin with the highest grade of intracranial hemorrhage was
included.
Degree of maternal sedation was evaluated after administration of study drug. Neonatal
ultrasound exams were performed at 3-5 days, 10-14 days, and 38-42 wks postmenstrual age;
neonatal medications were recorded during the first week of life; treatments, and outcomes
were recorded through death, discharge, or 120 days, whichever occurred first.
Neurodevelopmental outcome was evaluated at 18-22 months corrected age by certified examiners
masked to treatment status.
Inclusion Criteria:
- Admission to a high risk perinatal unit or labor and delivery unit;
- 24 to 32 completed weeks gestation;
- Expected delivery within 24 hrs;
- Preterm labor or no labor with planned delivery for maternal-fetal indications;
Exclusion Criteria:
- Anticipated delivery within two hours
- Multiple congenital or chromosomal abnormalities in the fetus
- Multiple gestation with more than two fetuses
- Administration of phenobarbital during the pregnancy
- Administration of indomethacin within one week before admission
- Maternal platelet count of less than 100,000 per cubic millimeter
We found this trial at
11
sites
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
Click here to add this to my saved trials
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials